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Summary
Purpose: To quantify the impact of the diagnosis of leprosy and of visible
impairments in people affected by leprosy.
Subjects and Methods: Three interview-based questionnaires designed to measure
activity limitation, participation restriction, and general self-efficacy were used to
collect data from three Groups. Group 1: leprosy affected people with visible
impairment, Group 2: newly diagnosed leprosy patients with no visible impairment,
Group 3: patients with other skin diseases symptomatic for more than 1 month.
Results: One hundred and eight subjects were recruited. The subjects with visible
impairments (Group 1) had higher levels of participation restriction than those with
skin disease (P0·012), and participation restriction was similar between subjects in
Groups 2 and 3 (P0·305). The people in Group 1 (35 subjects) also reported
significantly more activity limitation compared to the people in either Group 2
(35 subjects) or Group 3 (38 subjects) (P 0·001, respectively). The subjects in Group 2
had no significant activity limitation compared with those in Group 3 (P0·338).
A multivariate analysis showed that severe visible impairment was a risk factor for
activity limitation (odds ratio 5·68, 95% CI: 1·09–29·7, P0·039) and a low level of self-
efficacy (Odds ratio 6·38, 95% CI: 1·06–38·3, P0·043) among people affected by
leprosy.
Conclusion: Visible impairments affected the activities and attitudes of people
affected by leprosy. However, others without visible impairment, had activity
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limitations, participation restrictions and levels of general self-efficacy that were
similar to patients with other skin diseases. Prevention of visible impairments should
be considered a key intervention for stigma reduction.
Introduction
In some societies, when people affected by leprosy have visible impairments, this can
evoke stigma.1,2 The ways in which visible impairments cause dehabilitation among
people affected by leprosy is described in detail by Kaur et al.3 To quantify this burden
three instruments – the Participation scale (P-scale), Screening of Activity Limitation and
Safety Awareness (SALSA) scale, and the General Self-efficacy (GSE) scale – can be
used. The P-scale can be used as a proxy measure of stigma.4,5 The SALSA scale is a new
measurement scale for activity limitation in the daily lives of people suffering affects of
peripheral neuropathy.6 The GSE scale7 measures people’s beliefs about their capabilities
to produce designated levels of performance that exercise influence over events that affect
their lives.8
For patients who suffer from chronic and stigmatising illness, participation restriction can
be more important than the underlying health condition. However, participation is a relatively
new concept, and so there are few instruments to measure it.5,9 The P-scale was designed to
measure participation restriction in low and middle income countries.5,9 This scale has been
tested on patients in rural and urban settings.5 There are two studies which used this scale to
assess people affected by leprosy.10,11 Nicholls et al. used the scale to select subjects for an
analysis of the risk factors which could cause participation restriction in Brazil, India,
and Nepal.11 Cross and Choudhary used this to evaluate the effect of stigma elimination
campaign in Nepal.10
The SALSA scale measures activity limitation in daily life, and was specifically designed
for assessing patients with peripheral neuropathy and disability. It was based on the research
in diabetic and leprosy patients.6 SALSA also assesses the safety awareness in the daily
lives of people.6,9
The GSE score has been translated in 28 languages and validated in many countries in
various settings.12,13 Individuals’ ability to cope with difficulties in their lives can be hindered
by a lack of confidence. ‘Perceived self-efficacy is defined as people’s beliefs about their
capabilities to produce designated levels of performance that exercise influence over events
that affect their lives’.8 Self-management based on self-efficacy is essential in the management
of chronic illness,14 such as leprosy. However, low self-efficacy could be an obstacle because
‘self-perceived inefficacy can and does nullify the motivating potential of desirable outcome
expectancies’,15 which could introduce a vicious cycle combined with deterioration of the
visible impairments.
We used these three scales together to quantify the impact of diagnosis of leprosy and
visible impairments in people affected by leprosy. We hypothesised that people affected
by leprosy would feel the highest level of participation restriction, activity limitation, and
the lowest level of self-efficacy amongst these three groups of people; that patients with other
skin diseases would be least affected; and that recently diagnosed leprosy patients without
any visible impairment would have intermediate levels of restriction.
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Subjects and Methods
Approval from the Ethics committee at London School of Hygiene and Tropical Medicine
and Institutional Review Board at Leonard Wood Memorial (LWM) were obtained.
After a review of clinical charts, people aged between 16 and 45 years were recruited
from the two LWM clinics in Cebu, the Philippines: Cebu Skin Clinic (CSC) and the
LWM Clinical Branch (CB). CB is located in the Eversley Childs Sanitarium (ECS) which
has an adjacent colony (ECS community) populated predominantly by people affected
by leprosy, their families and other relatives. Some of the people affected by leprosy who
live there routinely attend the CB. The study subjects were categorised into the following
three Groups.
Group 1: People affected by leprosy with visible impairments
Group 2: Leprosy patients without any visible impairment diagnosed with leprosy within
the 6 months prior to the study.
Group 3: Patients with other skin diseases who had been symptomatic for more than
1 month prior to the study.
INSTRUMENTS
The P-scale has 20 questions with responses scored either 0 to 3 or 5. The sum score
suggests the level of participation restriction that a respondent perceives. According to
van Brakel et al. the following participation restriction scores apply5:
. 0 to 12 – no significant participation restriction
. 13 to 22 – mild participation restriction
. 23 to 32 – moderate participation restriction
. 33 to 52 – Severe participation restriction
. 53 to 90 – Extreme participation restriction
The SALSA scale consists of 18 questions with answers scored between 0 and 4. The sum
score suggests the level of activity limitation but it is also possible to calculate the level of
safety awareness which may be a factor that prevents certain activities.
The GSE scale has 10 statements with responses scored between 1 and 4. The sum scores
were compared between three Groups. A high SALSA score was defined as that above
75 percentile and low GSE score as that below 25 percentile of whole study population.
Participation restriction was defined as the score above 12.5
For subjects in Group 1, visible impairments on hands and feet were graded and scored using
a classification of hand and foot impairment according to severity of impairment (Table 1).
The only eye impairment to be recorded was lagophthalmos. The sum score above
50 percentile of that obtained from the patients in Group 1 were categorised as severe
visible impairment.
People in Group 3 had their skin diseases diagnosed by physicians at the CSC. Localised
lesions without active inflammation were classified as mild, generalised lesions, lesions with
active inflammation, or unbearable conditions were classified as severe, others were classified
as moderate.
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STATISTICAL ANALYSIS
All analyses were done by STATAe10.0 (StataCorp, Texas, USA). For categorical data,
chi-square and Fischer’s exact test were applied. For continuous data, either ANOVA
or Kruscal Wallis test was applied. Scores obtained from interviews were compared
between three groups. Logistic regression analysis was applied to identify risk factors for
participation restriction, activity limitation, and low perception of general self efficacy.
Results
One hundred and eight subjects were recruited (Table 2).
The subjects in Group 1 had significantly less education at secondary and tertiary
level than those in Group 2 or 3.
Diagnosis of other skin diseases amongst subjects in Group 3 included: 13 contact/allergic
dermatitis (34%); 7 tinea infection (18%); 4 seborrheic dermatitis (11%); 3 psoriasis (8%);
2 prurigo nodularis (5%) cases; 2 acune (5%) cases; and 7 other conditions/diseases (18%) were
coagulopathy suspected (pytiriasis rosea, striae distensae, carbunculosis, neurodermatitis,
verruca plana, and lichen planus). Twenty two (58%) were categorised as mild, 12 (31%)
moderate, and 4 (11%) severe.
The 75th percentile in the range of SALSA scores, the 25th percentile in the range of GSE
scores, and the 50th percentile of the impairment grading scores for the study population
were 28·5, 32, and 7·5, respectively, and the subjects in those categories in each
interview/examination were labelled as high SALSA, low GSE score, and severe visible
impairment, respectively (Table 3).
Significantly more patients in Group1 reported participation restriction than those in
Group 3 (Table 3). The Group 1 subjects had the highest SALSA scores whilst the SALSA
scores for Groups 2 and 3 were similar. The GSE score was similar between all three Groups.
Table 1. Classification of Hand and foot Impairment and Scoring
Classification of Hand Impairment
Grade 1 Anesthesia
Grade 2.1 Wound but no other impairment
Grade 2.2 Ulnar weakness (mobile claw fingers)
Grade 2.3 Ulnar paralysis (fixed claw fingers) and/or loss of phalanges (not including
proximal phalanges and not including thumb)
Grade 2.4 As grade 2.2 but also with loss of any proximal phalanx or median paralysis
(loss of opposition)
Grade 2.5 As with grade 2.2 and median paralysis (loss of opposition)
Grade 2.6 Radial paralysis (wrist drop) or mitten hand (no fingers or thumb)
Grading Foot Impairment
Grade 1 Anesthesia
Grade 2.1 Wound but no other impairment or foot drop accompanied by any sensory loss on
the same foot
Grade 2.2 Claw toes or loss of any small toes (i.e. NOT hallux)
Grade 2.3 Loss of hallux
Grade 2.4 Loss of hallux and claw toes
Grade 2.5 Loss of any bones proximal to the small toes or hallux
Grade 2.6 Tarsal disintegration (‘boat foot’)
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Univariate analysis was done to identify the risk factors for participation restriction,
high SALSA scores and low GSE scores. The variables analysed were: visible impairments
(Group 1 or not), age ($30), sex (female), working status, marital status, living with family
or not, final education at primary level, living in ECS community, history of steroid
treatment, and severe visible impairment (Table 4).
Living in ECS community was the only variable identified as a risk factor for participation
restriction although whether living at ECS is a cause or an effect of participation restriction
was not established.
Table 2. Demographic data of the subjects
Group 1 Group 2 Group 3
Number of subjects 35 35 38
Number of males (%) 25 (71%) 28 (80%) 24 (63%) P ¼ 0·283
Age (median) 29 (25, 35) 27 (22, 34) 7 (21, 38) P ¼ 0·335
Working status P ¼ 0·838
Currently on full-time job 16 (46%) 17 (49%) 20 (53%)
Currently not working 19 (54%) 18 (51%) 18 (47%)
Marital status P ¼ 0·748
Single 22 (63%) 24 (69%) 27 (71%)
Married or living with partner 13 (37%) 11 (31%) 11 (29%)
Final education level P , 0·001
Primary 17 (48%) 3 (9%) 3 (8%)
Secondary 10 (29%) 22 (63%) 17 (45%)
Tertiary 8 (23%) 10 (29%) 18 (47%)
Living condition P , 0·001
With family, partner or relatives 15 (43%) 33 (94%) 30 (79%)
With other people (patients etc) 20 (57%) 2 (6%) 5 (13%)
Alone 0 0 3 (8%)
Living inside ECS community 26 (74%) 1 (3%) 0 P , 0·001
Duration living in ECS community
, 1 year 4 (11%) 0 NA
1–3 years 6 (17%) 0 NA
3–6 years 6 (17%) 0 NA
6–10 years 3 (9%) 0 NA
. 10 years 7 (20%) 1 (3%) NA
Ridley-Jopling Classification
LL 10 (29%) 25 (71%) NA
BL 6 (17%) 7 (20%) NA
BB 2 (6%) 1 (3%) NA
BT 6 (17%) 1 (3%) NA
TT 0 0 NA
I 0 1 (3%) NA
Unknown 11 (31%) 0 NA
History of steroid medication 28 (80%) 17 (49%) NA P , 0·001
Current steroid prescription 10 (29%) 17 (49%) NA P , 0·001
History of clofazimine treatment 8 (23%) 0 NA
Current clofazimine treatment 1 (3%) 0 NA
1. Numbers in ( ) in age shows 25 and 75 percent quartile.
2. We could not get the information on leprosy type from 11 patients in Group 1, who had completed MDT a long
time previously elsewhere, admitted to the ECS for wound care, and did not have detailed records and few scar or
lesion on the surface.
3. P values shown in the right column represent difference between three groups. P values less than 0·05 indicates
statistically significant difference.
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Risk factors for a high SALSA score included: Visible impairments, final education
at primary level, living in ECS community, and severe visible impairment.
The only risk factor for a low GSE score was severe visible impairment.
Table 5 shows a multivariate analysis for the risk factor for participation restriction,
high SALSA score, and/or low GSE.
The variables analysed were: visible impairments (Group 1 or not), severe visible
impairment, final education at primary level, and living in the ECS community. Severe visible
impairment was identified as a significant risk factor for high SALSA and low GSE score.
Table 3. Participation restriction, SALSA score, GSE and visible impairments in the three groups of participants
Group 1 Group 2 Group 3
Number of participants 35 35 38
Participation restriction P ¼ 0·019*
No (0–12) 18 (51%) 25 (71%) 31 (82%)
Yes (13–90) 17 (49%) 10 (29%) 7 (18%)
SALSA score (median) 31 (25, 40) 23 (19, 24) 23 (20, 25) P , 0·001**
High SALSA score ($75 percentile (28·5)
of study population)
22 (63%) 3 (9%) 2 (5%) P , 0·001***
The GSE score (median) 33 (30, 36) 36 (33, 38) 34 (32, 37) P ¼ 0·271
Low GSE score (#25 percentile (32)
of study population)
12 (34%) 8 (23%) 11 (29%) P ¼ 0·572
Severe visible impairment ($50 percentile
(7·5) of Group 1)
18 (51%) NA NA
P values indicated in the right column show the result of chi-square and Fischer’s exact test between three groups.
P values less than 0·05 was considered to be statistically significant and post-hoc analysis was performed for each
analysis as shown below:
*P ¼ 0·012 compared between Group 1 and 3, 0·086 between Group 1 and 2, and 0·305 between Group 2 and 3.
**P , 0·001 compared between either Group 1 and 3 or Group 1 and 2, and 0·338 between Group 2 and 3.
***P , 0·001 compared between Group 1 and 3, 0·023 between Group 1 and 2, and 0·345 between Group 2 and 3.
Table 4. Univariate analysis of risk factors for high SALSA score, participation restriction, and low GSE score
amongst subjects in Group 1 and 2
Participation restriction High SALSA score Low GSE score
Odds ratio
(95% CI)
P
value
Odds ratio
(95% CI)
P
value
Odds ratio
(95% CI)
P
value
Visible impairments
(Group 1 or not)
2·36 (0·88–6·34) 0·09 18·1 (4·60–70·9) ,0·001* 1·76 (0·61–5·05) 0·29
Age (above 30) 0·64 (0·23–1·80) 0·40 2·27 (0·82–6·27) 0·11 0·70 (0·23–2·13) 0·53
Sex (female) 1·16 (0·38–3·52) 0·80 1·36 (0·44–4·17) 0·59 1·06 (0·32–3·51) 0·93
Working status 0·66 (0·25–1·74) 0·40 0·64 (0·24–1·72) 0·37 0·67 (0·23–1·91) 0·45
Marital status 1·21 (0·44–3·34) 0·70 0·85 (0·30–2·41) 0·76 1·42 (0·48–4·15) 0·53
Living with family or not 0·50 (0·18–1·40) 0·19 0·09 (0·03–0·28) ,0·001* 0·58 (0·20–1·73) 0·33
Final education at
primary level
1·73 (0·90–7·52) 0·08 4·27 (1·43–12·8) 0·009* 1·53 (0·50–4·67) 0·45
Living in ECS community 3·22 (1·18–8·87) 0·02* 14·7 (4·44–48·4) ,0·001* 1·45 (0·51–4·17) 0·49
History of steroid treatment 2·77 (0·93–8·23) 0·07 1·29 (0·46–3·63) 0·63 1·43 (0·47–4·36) 0·53
Severe visible impairment 2·57 (0·86–7·70) 0·09 21 (5·08–86·8) ,0·001* 3·73 (1·19–11·6) 0·024*
*P values less than 0·05 was considered to be statistically significant.
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Discussion
People affected by leprosy with visible impairments (Group 1) reported more significant
activity limitation and participation restriction compared to those with other skin diseases
(Group 3). Recently diagnosed leprosy patients without visible impairments (Group 2) were
similar in activity limitation or participation restriction when compared to those with other
skin diseases.
It is not surprising that the subjects in Group 1 reported the highest SALSA scores
because as patients have more severe impairment so they will have activity limitations.
However, some subjects in Groups 2 and 3 also had relatively high SALSA scores: these
patients were having leprosy reactions or were anaemic; this suggests that SALSA is also
sensitive to impaired general conditions. Further evidence that impairments per se, may not
predict high SALSA scores is illustrated in the following example: the subject who had the
highest SALSA score (68) in Group 1 had a right wrist drop and some minor clawing of the
toes, whereas another subject who scored 30 on SALSA also scored the highest impairment
score; that subject had bilateral lagophthalmos, bilateral median paralysis, loss of the hallux
on the right foot, and bone absorption of proximal phalanx of the small toe on the left foot.
We postulate that this subject had adapted to his impairments and had found alternative
methods to conduct his activities.
Regarding P Scale results, the finding that subjects in Group 2 did not show any
significant participation restriction compared to subjects in Group 3 was important.
The finding suggests that the diagnosis of leprosy per se does not cause people to perceive any
greater disadvantage than people diagnosed with other skin conditions. Physicians at Cebu
Skin Clinic reported that most patients listen to the diagnosis calmly especially after they are
reassured that leprosy is curable. MDT was introduced to the Philippines 20 year ago16 so
awareness of the disease and the treatment thereof may have had a positive effect on the
population, which could also mitigate the negative impact of the diagnosis on the subjects in
Group 2 who were diagnosed later compared to those in Group 1, as some of the subjects in
Group 1 were diagnosed in 1990s or earlier. A laboratory worker at LWM located in ECS
Table 5. Risk factor for high SALSA score, participation restriction, and low GSE score among patients in
Group 1 and 2
Participation restriction High SALSA score Low GSE score
Odds ratio (95% CI) P value Odds ratio (95% CI) P value Odds ratio (95% CI) P value
Visible impairment
(Group 1 or not)
0·88 (0·18–4·32) 0·88 4·14 (0·66–26·1) 0·13 0·91 (0·20–6·09) 0·91
Severe visible
impairments
1·22 (0·28–5·25) 0·79 5·68 (1·09–29·7) 0·039*1 6·38 (1·06–38·3) 0·0432
Final education at
primary level
1·60 (0·46–5·56) 0·46 0·88 (0·18–4·14) 0·97 1·03 (0·25–4·14) 0·97
Living in ECS
community
2·61 (0·52–13·2) 0·25 3·00 (0·54–16·5) 0·21 0·42 (0·06–2·91) 0·38
*P values less than 0·05 was considered to be statistically significant.
1R2 ¼ 0·363.
2R2 ¼ 0·074.
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reported that during the1990s people would stare at staff as they entered the sanitarium,
but that this no longer occurs. ECS now has a functioning general hospital and is no longer
solely as sanitarium. Whether the subject belonged to Group 1 or not might have reflected the
time difference some extent although it was not identified to be significant in this study.
The sample size was too small to do detailed sub-analysis. The small sample size could also
obscure the difference between Group 1 and 2 regarding the participation restriction as
the recommended sample size is noted as 50 for P-scale application.5
Our sample size was constrained because participant recruitment was done during a
four-week study period. CSC had 52 newly diagnosed patients aged between 16 and 45 during
the previous six months, which was the maximal number of subjects for Group 2, but we were
only able to contact 35. During the study period, we simultaneously recruited the candidates
for Group 3 who met the inclusion criteria. Group 1 subjects were taken from the 212 people
aged between 16 and 45 followed by CB and ECS annually, we strictly applied the inclusion
criteria and recruited only the subjects who had visible impairments.
There were significant levels of perceived participation restriction amongst people with
visible impairments. This may be because the impairments physically restrict their abilities to
participate socially or it could be that such individuals suffer the effects of an insidious type
of stigma: i.e. people may discriminate against them for reasons as yet poorly understood
(it may be that people are fearful of their appearance, or there could be deeply rooted cultural
beliefs which attribute blame on people adversely affected by leprosy). Alternatively, it may
be that people with visible impairments perceive stigma which is not intended or that they
voluntarily withdraw as an effect of shame (self stigma). It is essential to expand the current
knowledge of these important but neglected factors.
The finding that living in the ECS community was a risk factor for participation restriction
should be interpreted cautiously because this might reflect a reverse causal relationship.
Some subjects reported that they were living in ECS because their families preferred
living there. Cross and Choudhary reported that good levels of family and community support
reduced the stigma against people affected by leprosy in Nepal,10 which supports the
suggestion of reverse causal relationship in this study. Some subjects in Group 2 were found to
have high levels of participation restriction, and these might only be understood by using more
detailed interviews.
Being categorised in Group 1, having visible impairments, overlaps with other factors, such
as living in ECS community. As 74% of the subjects in Group 1 were recruited from ECS
community, the impact of this factor might have been different if the participants had been
recruited from wider community. Socio-economic backgrounds and the effect of diagnosis of
leprosy might be differentially bound in each subject. Recruiting the subjects from wider
community could also mitigate the difference in socio-economic backgrounds between groups.
The GSE score was similar in the three groups, however, severe visible impairment was
identified as a risk factor for low GSE score. A larger study might alter this effect because
a higher proportion of patients with severe visible impairment in Group 1 (9/18, 50%) had
lower GSE score than those with less severe impairment (3/17, 18%), whereas the proportion of
the patients with low GSE score in Group 2 was 23% (8/35).
LIMITATION OF THE STUDY
Although some risk factors were identified through the univariate analysis, fewer were
identified as a risk factor in multivariate analysis. This could have been due to a small sample
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size; a larger sample in terms of both number and the area of recruitment will give clearer
indications. This was a relatively small, one-point case control study in which it was not
possible to consider all the factors that may have been significant. It would have been useful
to conduct a comprehensive analysis of socio-economic status and community dynamics,
greater study of the actual causal relationships between risk factors and results would also
have been enlightening.
Conclusion
Visible impairments did impact on the activities and attitudes of people affected by
leprosy, however, the diagnosis of leprosy per se did not have significant impact. If the
potential for leprosy to cause impairments could be addressed, the stigma of leprosy
might be eliminated. This was a small one-point, case–control study; further prospective
follow-up studies of people newly diagnosed with leprosy will be useful to investigate
the true causal relationship between risk factors and the results. To procure an adequate
sample size and to be able to validate conclusions a multi-centre study might be more
desirable.
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